Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
0.740
+0.058 (8.54%)
At close: Jan 21, 2025, 4:00 PM
0.743
+0.003 (0.41%)
After-hours: Jan 21, 2025, 7:59 PM EST
Cognition Therapeutics Employees
As of December 31, 2023, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees increased by 3 or 12.00% compared to the previous year.
Employees
28
Change (1Y)
3
Growth (1Y)
12.00%
Revenue / Employee
n/a
Profits / Employee
-$1,223,929
Market Cap
30.75M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28 | 3 | 12.00% |
Dec 31, 2022 | 25 | 4 | 19.05% |
Dec 31, 2021 | 21 | 1 | 5.00% |
Dec 31, 2020 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CGTX News
- 13 days ago - Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - GlobeNewsWire
- 4 weeks ago - Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? - Benzinga
- 4 weeks ago - Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population - GlobeNewsWire
- 2 months ago - Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - GlobeNewsWire
- 2 months ago - Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum - GlobeNewsWire
- 2 months ago - Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD - GlobeNewsWire